Research in The Lancet once again underscores the effectiveness of chemotherapy for hormone-receptor-negative breast cancer. It also shows that tamoxifen has little effect on recurrence or death for hormone negative patients.
Breastcancer.org has a good overview of the research, which uses data from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
The study looked at chemo from the 1970s and 1980s, which has been shown to be less effective than newer regimens.
No comments:
Post a Comment